Search

Background: Yoga originated in the territory of modern India more than 3,000 years ago uses techniques for working with the musculoskeletal system, cardiorespiratory system, and attention. Currently, the effectiveness and safety of yoga in patients with various neurological disorders, including multiple sclerosis (MS), is of interest to many scientists and clinicians. Purpose: The main aim of this study is to examine the effect of yoga on symptoms and quality of life in patients with MS vs physical therapy (exercise therapy) and no exercise. Methods: The patients were randomly assigned to three groups (yoga, physical therapy (PT), or waiting list). After 12 weeks of regular exercises (or the absence of them), the effect of yoga and PT on the functional status and quality of life of patients were evaluated. The data were collected during the patients' two visits to the study center – before the start of the study and at the end of the 12-week period. The in-person examination included a doctor's assessment of the Expanded Disability Status Scale (EDSS), the SF-36 quality of life questionnaire, the fatigue scale, the Berg balance scale, and the 6-min walking test. Results: A total of 36 patients finished the clinical study: thirty women and six men. There was no statistically significant difference between the groups in terms of improvement in MS symptoms as measured by the balance, walking test, and fatigue scales. However, in the analysis of eight criteria of SF-36 quality-of-life questionnaire by the covariation analysis, statistically significant differences were found in favor of the yoga group in terms of physical functioning (PF) (p =.003), life activity (VT) (p <.001), mental health (MH) (p = 013), and social functioning (SF) (p =.028). Conclusion: Thus, regular yoga classes under the guidance of qualified staff are a promising method of non-drug rehabilitation of patients with MS with motor disorders. [ABSTRACT FROM AUTHOR]

Background: Pediatric investigation plans (PIPs) describe how adult drugs can be studied in children. In 2015, PIPs for Amyotrophic Lateral Sclerosis (ALS) became mandatory for European marketing-authorization of adult treatments, unless a waiver is granted by the European Medicines Agency (EMA). Objective: To assess the feasibility of clinical studies on the effect of therapy in children (<18 years) with ALS in Europe. Methods: The EMA database was searched for submitted PIPs in ALS. A questionnaire was sent to 58 European ALS centers to collect the prevalence of pediatric ALS during the past ten years, the recruitment potential for future pediatric trials, and opinions of ALS experts concerning a waiver for ALS. Results: Four PIPs were identified; two were waived and two are planned for the future. In total, 49 (84.5%) centers responded to the questionnaire. The diagnosis of 44,858 patients with ALS was reported by 46 sites; 39 of the patients had an onset < 18 years (prevalence of 0.008 cases per 100,000 or 0.087% of all diagnosed patients). The estimated recruitment potential (47 sites) was 26 pediatric patients within five years. A majority of ALS experts (75.5%) recommend a waiver should apply for ALS due to the low prevalence of pediatric ALS. Conclusions: ALS with an onset before 18 years is extremely rare and may be a distinct entity from adult ALS. Conducting studies on the effect of disease-modifying therapy in pediatric ALS may involve lengthy recruitment periods, high costs, ethical/legal implications, challenges in trial design and limited information. [ABSTRACT FROM AUTHOR]

Respiratory failure, malnutrition, aspiration pneumonia, and dehydration are the precursors to mortality in ALS. Loss of natural communication is considered one of the worst aspects of ALS. This first study to test the feasibility of a music therapy protocol for bulbar and respiratory rehabilitation in ALS employs a mixed-methods case study series design with repeated measures. Newly diagnosed patients meeting the inclusion criteria were invited to participate, until the desired sample size (n = 8) was achieved. The protocol was delivered to participants in their homes twice weekly for six weeks. Individualised exercise sets for independent practice were provided. Feasibility data (recruitment, retention, adherence, tolerability, self-motivation and personal impressions) were collected. Bulbar and respiratory changes were objectively measured. Results. A high recruitment rate (100%), a high retention rate (87.5%) and high mean adherence to treatment (95.4%) provide evidence for the feasibility of the study protocol. The treatment was well tolerated. Mean adherence to the suggested independent exercise routine was 53%. The outcome measurements to evaluate the therapy-induced change in bulbar and respiratory functions were defined. Findings suggest that the protocol is safe to use in early- and mid-stage ALS and that music therapy was beneficial for the participants' bulbar and respiratory functions. Mean trends suggesting that these functions were sustained or improved during the treatment period were observed for most outcome parameters: Maximal Inspiratory Pressure, Maximal Expiratory Pressure, Peak Expiratory Flow, the Center for Neurologic Study—Bulbar Function Scale speech and swallowing subscales, Maximum Phonation Time, Maximum Repetition Rate—Alternating, Maximum Repetition Rate—Sequential, Jitter, Shimmer, NHR, Speaking rate, Speech–pause ratio, Pause frequency, hypernasality level, Time-to-Laryngeal Vestibule Closure, Maximum Pharyngeal Constriction Area, Peak Position of the Hyoid Bone, Total Pharyngeal Residue C24area. Conclusion. The suggested design and protocol are feasible for a larger study, with some modifications, including aerodynamic measure of nasalance, abbreviated voice sampling and psychological screening. [ABSTRACT FROM AUTHOR]

Objectives: To estimate the incidence of amyotrophic lateral sclerosis (ALS) in Moscow by investigating multiple sources of cases. Incidence rates from previous Russian studies ranged from 0.3 to 0.7 per 100,000/year. Methods: A retrospective study of the incidence of ALS was performed in the South district of Moscow (population, 1,760,000, 2015). Several data sources were investigated. The medical records of the calendar year 2015 were examined by an ALS expert who accepted only patients with definite or probable ALS according to the revised El Escorial criteria. Crude and standardized incidence rates were calculated, the latter adjusted to the Russian and the European population. Results: Twenty-two patients were found, accounting for a crude incidence of 1.25/100,000/year (95% CI 0.78–1.89) and a standardized incidence of 1.22 (Russia) and 1.28 (Europe). The sample included 11 men and 11 women aged 36–73 years (mean 56). Five patients (23%) had bulbar onset ALS. The mean diagnostic delay was 12.8 ± 9.2 months (8.5 ± 4.8 in men and 17.2 ± 10.6 in women) (p = 0.02). Family history of ALS was present in two cases. Conclusion: The incidence of ALS in the Russian Federation is higher than previously reported but lower than in other countries. Poor diagnostic ascertainment, particularly in women, and the shorter life expectancy of the Russian population are possible explanations. [ABSTRACT FROM AUTHOR]

Autologous haematopoietic stem cell transplantation (aHSCT) is a recognized therapy for multiple sclerosis (MS) and other autoimmune neurologic conditions. We performed a retrospective analysis of MS patient cohort, that was referred to Abu Dhabi stem cell center for this therapy during 2021-2022. We included patient with MS and clinically isolated syndrome (CIS). Patients with other neurological disorders were excluded from the study. 45 patients were included in the study (26 females and 17 males). 1 patient had CIS, 22 patients had remitting relapsing MS (RRMS), 16 patients had secondary progressive MS (SPMS), 6 patientS had primary progressive MS (SPMS). The mean age of RRMS group was 28.5 ± 6.7 years, of SPMS group 43.3 ± 12.2 years, and of PPMS group 51.8 ± 10.3 years. Median disease duration in RRMS group was 109 (14;206) months, in SPMS group 170 (125;1423) months and in PPMS group 166 (49;206) months. The Expanded Disability Status Scale (EDSS) score in RRMS group was 2 (1; 4.5), in SPMS group 6 (4.2; 6.1) and in PPMS group 6.75 (6.5; 7.5). Out of 22 RRMS patients, 8 had one relapse in the last 12 months and 3 had 2 or more relapses. 7 patient had new lesions on the magnetic resonance imaging (MRI). Patients were classified according to guidelines and recommendations from the European bone marrow transplantation (EBMT) Autoimmune Diseases Working Party. Three patients (6,7%) from our cohort were in the group of highly active RRMS failing to DMTs. aHSCT is a standard of care for this group of patients if their EDSS is 5.5 or less, they are younger than 45 years, and have disease duration less than 10 years. aHSCT was performed for two patients, whilst 2 patients didn't fulfill the additional criteria for disease duration and level of EDSS. Two patients (4,4%) were in the group aggressive (malignant) MS not previously treated with a full course of DMT. We performed aHSCT for one of the patients in this group. Other two patients (4,4%) had progressive MS with active inflammatory component. EBMT guidelines suggest to perform aHSCT in this group in a prospective clinical trial. Thirty-eight patients (84,4%) were either RRMS or progressive MS without active inflammatory component. Our data shows that most MS patients referred for aHSCT, do not have active inflammatory component of the disease, which is the main therapeutic target of the treatment. Rather a large proportion of patients had long disease duration and advanced stage of the disease which are poor prognostic factors for effectiveness of the treatment. We should improve awareness about aHSCT as a standard of care within the therapeutic window for MS patients younger than 45 years with EDSS less then 5,5 as per existing guidelines. [ABSTRACT FROM AUTHOR]

Multiple sclerosis is a chronic demyelinating disorder of the central nervous system. There are many cases of multiple sclerosis – like syndrome and demyelinating disorders in systemic lupus erythematosus, Sjogren disease, Behcet disease and other autoimmune conditions. Coexistence of ankylosing spondylitis and multiple sclerosis usually is rare but in this article we report 4 Russian patients with concomitant multiple sclerosis and ankylosing spondylitis diseases. None of these patients received anti-tumor necrosis factor alpha therapy prior to diagnosis of multiple sclerosis. Pathogenesis, diagnostic and treatment challenges are discussed. [ABSTRACT FROM AUTHOR]